| Outcome Measures: |
Primary: Saxagliptin Maximum Observed Concentrations (Cmax), 5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state, Day 1-3 (Period 1) and Day 8-10 (Period 2)|Dapagliflozin Maximum Observed Concentrations (Cmax), 5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state, Day 1 to 3 (Period 1) and Day 8 to 10 (Period 2)|Saxagliptin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T]), 5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state, Day 1-3 (Period 1) and Day 8-10 (Period 2)|Dapagliflozin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T]), 5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state, Day 1-3 (Period 1) and Day 8-10 (Period 2)|Saxagliptin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]), 5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state, Day 1-3 (Period 1) and Day 8-10 (Period 2)|Dapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]), 5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state, Day 1-3 (Period 1) and Day 8-10 (Period 2) |
|
